_PRIVATE_LIMITED.webp)
A S Pharmaceutical (India) Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 29-07-2024
- Paid Up Capital ₹ 1.21 Cr
as on 29-07-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.75 M
as on 29-07-2024
- Revenue -61.01%
(FY 2023)
- Profit -98.28%
(FY 2023)
- Ebitda -88.54%
(FY 2023)
- Net Worth 0.06%
(FY 2023)
- Total Assets -13.33%
(FY 2023)
About A S Pharmaceutical (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.21 Cr.
The company currently has active open charges totaling ₹5.75 M.
Sandhya Ajan and Gopinathan Ajan serve as directors at the Company.
- CIN/LLPIN
U24230TN2010PTC076676
- Company No.
076676
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at A S Pharmaceutical (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gopinathan Ajan  | Managing Director | 21-Jul-2010 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sandhya Ajan | Director | 21-Jul-2010 | Current |
Financial Performance of A S Pharmaceutical (India).
A S Pharmaceutical (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 61.01% decrease. The company also saw a substantial fall in profitability, with a 98.28% decrease in profit. The company's net worth moved up by a moderate rise of 0.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of A S Pharmaceutical (India)?
In 2023, A S Pharmaceutical (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Travancore Creation Date: 28 Apr 2011 | ₹5.75 M | Open |
How Many Employees Work at A S Pharmaceutical (India)?
A S Pharmaceutical (India) has a workforce of 3 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of A S Pharmaceutical (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped A S Pharmaceutical (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
